• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
75,415.35 231.99
( 0.31%)
Global Indices
Nasdaq
50,600.73 294.06
(0.58%)
Dow Jones
7,493.73 27.01
(0.36%)
Hang Seng
63,328.42 1,644.28
(2.67%)
Nikkei 225
10,474.02 30.55
(0.29%)
Forex
USD-INR
96.29 -0.42
(-0.43%)
EUR-INR
111.82 -0.44
(-0.39%)
GBP-INR
129.28 -0.40
(-0.31%)
JPY-INR
0.61 0.00
(-0.48%)

EQUITY - MARKET SCREENER

Lyka Labs Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
500259
INE933A01014
37.0210703
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
LYKALABS
0
220.39
EPS(TTM)
Face Value()
Div & Yield %
0
10
0
 

Puravankara reports consolidated net profit of Rs 113.24 crore in the March 2026 quarter
May 19,2026
Net profit of Puravankara reported to Rs 113.24 crore in the quarter ended March 2026 as against net loss of Rs 85.82 crore during the previous quarter ended March 2025. Sales rose 177.33% to Rs 1501.92 crore in the quarter ended March 2026 as against Rs 541.57 crore during the previous quarter ended March 2025.

For the full year,net profit reported to Rs 63.71 crore in the year ended March 2026 as against net loss of Rs 179.88 crore during the previous year ended March 2025. Sales rose 85.73% to Rs 3739.83 crore in the year ended March 2026 as against Rs 2013.61 crore during the previous year ended March 2025.

ParticularsQuarter EndedYear Ended
Mar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var.
Sales1501.92541.57 177 3739.832013.61 86
OPM %20.055.61 -18.4714.45 -
PBDT155.74-99.62 LP 118.87-178.12 LP
PBT144.96-110.81 LP 76.87-213.08 LP
NP113.24-85.82 LP 63.71-179.88 LP